Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PARL | Q9H300 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15371562 | 0.86 | KMT2A (0.32) | MGLLKMT2AATMGAA | |
| SCHEMBL19447705 | 0.86 | KMT2A (0.32) | MGLLKMT2AATM | |
| SCHEMBL17447 | 0.85 | MGLL (0.37) | MGLLGLAPARL | |
| SCHEMBL9546740 | 0.82 | MGLL (0.33) | MGLLKMT2AATMALDH1A1HPGD | |
| SCHEMBL9546488 | 0.82 | MGLL (0.33) | MGLLKMT2AATMALDH1A1HPGD | |
| SCHEMBL2139612 | 0.81 | MGLL (0.35) | MGLLPARL | |
| SCHEMBL15591345 | 0.81 | CCNE1 (0.34) | MGLLBRD4 | |
| SCHEMBL18947917 | 0.81 | MGLL (0.31) | MGLL | |
| SCHEMBL726706 | 0.81 | MGLL (0.37) | MGLLKMT2AATMALDH1A1HPGD | |
| SCHEMBL21582363 | 0.79 | BRD4 (0.35) | KMT2AATMBRD4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114890916-A | Preparation method of N-methoxycarbonyl-L-tert-leucine | 常州吉恩药业有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-114685316-A | MOC-L-valine synthesis process | 常州吉恩药业有限公司 | 2022-07-01 | — | — | CN | claimed |
| EP-4649086-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4622959-A1 | 2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-3706747-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025094035-A1 | TOLL-LIKE RECEPTOR AGONISTS AND CONJUGATES THEREOF | PFIZER INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD THERAPEUTICS LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| WO-2024151465-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024112621-A1 | 2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2006012725-A1 | LYSINE BASED COMPOUNDS | AMBRILIA BIOPHARMA INC. (CA) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025592-A1 | Lysine based compounds | TAIMED BIOLOGICS, INC. (TW) | 2006-02-02 | — | — | US | disclosed |
| CN-1690193-A | Use of methioninase in anti-methionine and anti-homocysteine chemotherapy | ANTICANCER INC (US) | 2005-11-02 | — | — | CN | disclosed |
| EP-1575914-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Procyon Biopharma Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| CN-1589257-A | N-methyl-homocysteine and application and preparation method thereof | SCHERING AG (DE) | 2005-03-02 | — | — | CN | disclosed |
| WO-2004056764-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2004-07-08 | — | — | WO | disclosed |
| US-6632816-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | PHARMACOR INC. (CA) | 2003-10-14 | — | — | US | disclosed |
| WO-1994018229-A1 | 1,2,4-TRIAZINONE DERIVATIVES AND THEIR USE IN THERAPY | FISONS CORPORATION (US) | 1994-08-18 | — | — | WO | disclosed |
| CN-1053607-A | The human immunity that is used for the treatment of AIDS lacks the inhibitor of virus protease | MERCK & CO INC (US) | 1991-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, MACROD1, MSN | MGLL 2707/4885KMT2A 2714/4885ATM 668/4885 |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | PRSS1, PRSS2, ACE2 | MGLL 1422/4885KMT2A 3149/4885ATM 2521/4885 |
| US-20060025592-A1 | Lysine based compounds | DOT1L, H1-2, H1-0 | MGLL 1640/4885KMT2A 12/4885ATM 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.